Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
272
resultados
Última actualización
30/10/2026 [06:55:00]
Resultados 250 a 272 de 272
Resumen de: US20260315404A1
0000 A prophylactic vaccine composition that is intended for mammals and birds comprises a killed whole bacterium, the bacterium being covered with a cationic agent, in particular, cationic nanoparticles.
Resumen de: WO2026214581A1
The present invention provides an anti-protein-adhesion cell-affinity zwitterionic polymer. The zwitterionic polymer is used as a drug delivery carrier. By regulating the hydrophilicity and hydrophobicity of a substituent of a zwitterionic unit, the zwitterionic polymer exhibits an anti-protein-adhesion property in blood circulation, and meanwhile, at a tumor site, adsorbs to a cell membrane to trigger rapid transcytosis, thereby achieving efficient tumor vascular extravasation and intratumoral penetration. The present invention solves the problem of low cellular uptake caused by a strong hydration effect of conventional zwitterionic carriers, and is suitable for targeted delivery of chemotherapeutic drugs, nucleic acids, protein drugs, and the like.
Resumen de: WO2026214438A1
The present application relates to a nanocarrier based on self-assembly of a protein and a hydrophobic polymer, a nano drug delivery system, a preparation method for the nanocarrier, and a use of the nanocarrier. The nanocarrier is nanoparticles formed by self-assembly of an amphiphilic protein and a hydrophobic polymer driven by hydrophobic interactions, wherein the hydrophobic polymer is encapsulated inside the nanoparticles by the amphiphilic protein. The nanocarrier has the advantages of high drug loading capacity, high encapsulation efficiency, high colloidal stability, good uniformity and production reproducibility, good dispersibility, good biocompatibility, a simple formulation, low energy consumption and the like. The nanocarrier can be used for drug delivery and can also be used for contrast-enhanced imaging of tumor sites. Moreover, drug molecules can be loaded at different positions of the nanocarrier on the basis of different requirements, and the nanocarrier has diverse structures and compositions, and can satisfy the requirements of different application scenarios.
Resumen de: WO2026214648A1
The present invention provides a lipid compound comprising a cyclic urea structure, and specifically relates to a compound of formula (I), or an isotopic variant, tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention also provides a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition comprising the compound in muscle-specific delivery of nucleic acids.
Resumen de: US20260317336A1
0000 An ionizable lipid, and a drug delivery system containing the ionizable lipid are provided. Specifically, the ionizable lipid may have the structure of formula (I). A pharmaceutically acceptable salt, tautomer, or stereoisomer of the ionizable lipid is also provided. A lipid nanoparticle constructed by means of using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small-molecule drugs, peptide drugs and protein drugs.
0000
Resumen de: US20260315596A1
The present invention discloses a hybrid metal-lipid nanoparticle for targeted therapy comprising properties of organic and inorganic nanoparticles (NPs), combined in a single formulation to obtain NPs with unique attributes. This will allow the synergistic effect between drug delivery (also known as chemotherapy) and photothermal therapy. This strategy relies on the construction of hybrid metallic-gold nanoparticles using a dual functionality by lipid nanoparticles (as organic components and drug delivery system) in the core and gold nanorods (as inorganic component and a heat delivery system) in the shell, linked by a tumor-targeting peptide. The active targeting strategy was implemented to guarantee a specific delivery to the brain by using transferrin (targeting the blood-brain barrier) and cRGDfK (not only used to target GB tumor barrier but also as a linker between both inorganic and organic nanoparticles).
Resumen de: US20260315624A1
0000 The present disclosure relates to a combination therapy comprising an immune checkpoint inhibitor, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug, and methods of treatment using such combination therapies and/or compositions.
Resumen de: US20260315598A1
0000 The present disclosure provides a photosensitizer chlorin e6 (Ce6)-loaded nanoparticle targeting mitochondria of a breast cancer cell, and a preparation method and use thereof, and belongs to the field of pharmaceutical preparations. In the present disclosure, the nanoparticle uses a hollow mesoporous silica nanoparticle (HMSN) as a carrier, a hollow position of the carrier is loaded with a photosensitizer Ce6, the carrier is externally encapsulated with a red blood cell membrane (RBCM), and the carrier after encapsulating the RBCM is modified with a Pt nanocluster on one side as well as an aptamer LXL-1 and 1-carboxypropyltriphenylphosphine bromide (TPP) on the other side.
Resumen de: US20260315620A1
A Magnetic Torquer (m-Torquer) conjugate-based drug is disclosed. The m-Torquer conjugate, containing: (a) a magnetic nanoparticle that generates rotational force upon application of a controlled rotating magnetic field, wherein the working distance from the rotating magnetic field generator is at least 1 cm, preferably at least 2 cm, 10 cm, more preferably at least 20 cm, 30 cm, and most preferably at least 60 cm or 70 cm; (b) a binding moiety that binds to a drug target protein present in the biological lipid membrane; and (c) a linker or a direct attachment between the magnetic nanoparticle and the binding moiety, wherein, when the m-Torquer conjugate binds to the drug target protein, the rotational force generated by the magnetic nanoparticle upon application of a controlled rotating magnetic field is transmitted to the drug target protein, inducing a conformational change in the drug target protein.
Resumen de: US20260317808A1
0000 The present invention relates to methods of determining the efficiency of RNA encapsulation in lipid nanoparticles (LNPs). In some embodiments, methods according to the present invention comprise a step a) of contacting a sample comprising RNA encapsulated in LNPs with a first fluorophore and a second fluorophore, thereby forming fluorophore-RNA complexes, and a step b) of detecting the fluorescence signals of the complexed first and second fluorophore, wherein the first fluorophore permeates the LNPs and wherein the second fluorophore does not permeate the LNPs.
Resumen de: US20260317273A1
The present invention addresses the problem of providing, without using relatively expensive starting materials, a more conveniently synthesizable pH-sensitive cationic lipid and a lipid nanoparticle that contains this pH-sensitive cationic lipid. The present invention is a pH-sensitive cationic lipid represented by general formula (I). R1 is a C1-22 hydrocarbon group; the three R1 groups in one molecule may be the same as or different from each other; Z1 is a C1-6 alkylene group or a single bond; X is —N(R2)(R3) or is a 5- to 7-membered nonaromatic heterocyclic group (with the proviso that this group is bonded to Z1 via a carbon atom); and R2 and R3 are each independently a hydrogen atom or a C1-4 hydrocarbon group, or R2 and R3 may be bonded to each other to form a 5- to 7-membered nonaromatic heterocycle.
Resumen de: WO2023146356A1
The present invention relates to an antibody-bound lipid nanoparticle comprising an antibody bound to a membrane scaffold protein, and more specifically relates to an antibody-bound lipid nanoparticle which comprises a lipid, and an antibody bound to a membrane scaffold protein, and which can be easily produced and has an excellent specific targeting ability.
Resumen de: WO2022221616A1
In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or grafi-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmimized egg product obtained from an egg- producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecaUs, Enterococcus faecalis eytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis. isolated Enterococcus faecal is eytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.
Resumen de: WO2022155524A1
The disclosure provides coronavirus mRNA vaccines, including vaccines directed against one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
Resumen de: MX2023001461A
The present disclosure provides LNPs comprising payload molecules, e.g., mRNA therapeutics, for the treatment of diseases or disorders, which would benefit from delivery of payload molecules to airway cells.
Resumen de: AU2026238128A1
Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle. ep e p
Resumen de: US20260315575A1
0000 Provided is a tyrosinase-based transdermal delivery system for treating vitiligo, having a core-shell structure, a core being tyrosinase, and a shell being a polymer shell. Double bonds are introduced into tyrosinase, and the surface of protein is coated with a polymer protection layer through in-situ polymerization to protect the activity of the tyrosinase, and promote the transdermal delivery of the tyrosinase. Tyrosinase nanogel can be controlled to be delivered to melanocytes deep in skin and hair follicles in a targeted manner by regulating and controlling polymerization conditions of the polymer shell to promote in-situ synthesis of melanin. The system can also load active small molecules with an anti-inflammatory function at a center of the tyrosinase, and the small molecules are released after being delivered to an inflammatory area of vitiligo in a targeted manner along with the tyrosinase nanogel, thereby relieving inflammation, and protecting the melanocytes from being damaged.
Resumen de: US2023020016A1
The present disclosure presents nanoparticle compositions for use in the treatment, prevention, or imaging of a disease (e.g., cancer), methods of treating, preventing, or imaging a disease in a subject in need thereof with the nanoparticle compositions, and methods of preparing the nanoparticle compositions of the disclosure. The nanoparticle compositions can include a magnetic nanoparticle ferric chloride, ferrous chloride, or a combination thereof, and a dextran coating functionalized with one or more amine groups.
Resumen de: US20260315409A1
The application refers to a pharmaceutical composition, containing elemene, a protein carrier, and oil for injection, having improved safety and stability.
Resumen de: WO2026217014A1
The group of inventions relates to chemistry, biotechnology and pharmaceutics, and more particularly to a method of packing low molecular weight compounds into biological micro- and nanoparticles, as well as to loaded nanoparticles produced using said method, a pharmaceutical composition containing said loaded nanoparticles, and the use of said loaded nanoparticles. The method includes the steps of: (a) concentrating initial biological nano- and/or microparticles in an isotonic buffer to a total particle volume of no less than 30%; (b) adding positively charged compounds or hydrophilic neutral compounds directly to the suspension of biological nanoparticles, or dissolving negatively charged compounds or hydrophobic compounds in helper lipids, such that the total volume of all the particles is no less than 30%; (c) incubating the obtained mixture; (d) extruding the mixture; (e) subsequently purifying the extrudate by gel exclusion chromatography. The result is that of widening the range of low molecular weight compounds that can be packed, allowing more efficient loading, and preserving the biological properties of micro- and nanoparticles after packing.
Resumen de: WO2026217662A1
Provided herein are methods of preparing a composition comprising an antibody-lipid nanoparticle conjugate, in which an antibody modified with a click chemistry ligand is introduced in-line following lipid nanoparticle formation and in-line dilution, ensuring homogeneous mixing and a favorable environment for antibody stability. Also provided herein are antibody-lipid nanoparticle conjugates prepared by such methods. Further provided herein are chips and instruments for use in preparing the antibody-lipid nanoparticle conjugate.
Nº publicación: US20260315403A1 15/10/2026
Solicitante:
GLOBAL TRADEMARKS INC [US]
Global Trademarks, Inc.
Resumen de: US20260315403A1
0000 An exosome-like nano vesicle formulation comprising: a neutral lipid; and at least three active ingredients selected from the group consisting of an extract, an osmolyte, and an antioxidant, and methods of use thereof, including methods of treating inflammation, increasing skin hydration, and reducing visible signs of aging in the skin.
BOPI
Sede Electrónica
